THE HARD NEWS BRIEF
The Pharmaceutical Society of Kenya (PSK) has formally petitioned Parliament to reject the proposed VAT shift on medicines in the Finance Bill 2026, warning the tax change will spike retail prescription prices by up to 20%.
Local pharmaceutical manufacturers face an immediate 16% cost penalty on raw materials as the bill seeks to transition active pharmaceutical ingredients (APIs) from zero-rated to exempt status, destroying input VAT claim mechanisms.
The National Assembly’s Finance and Planning Committee must now weigh a projected marginal increase in tax revenue against a severe contraction in domestic pharmaceutical production and a rise in healthcare costs.
How the Proposed VAT Shift on Medicines Pressures Households
Under the proposed tax amendments, reclassifying essential medicines from zero-rated to exempt prevents local drug manufacturers from reclaiming VAT on imported active pharmaceutical ingredients (APIs), packaging, and manufacturing utilities. Input VAT represents approximately 12% to 15% of the total cost of production. When these inputs are exempt, manufacturers cannot claim relief on this 16% VAT, forcing them to pass it directly to consumers at the retail pharmacy counter.
The timing of this fiscal shock is highly precarious. While overall inflation has stabilized at 4.8%, medical inflation in Kenya is already running at 8.5% annually. Standardizing VAT on these products will disproportionately impact patients managing chronic conditions such as hypertension, diabetes, and oncology. A monthly supply of insulin that currently retails at KES 3,500 could immediately jump to KES 4,200, an unsustainable increment for households already paying the 2.75% SHIF levy.
Imported finished pharmaceutical formulations, which constitute nearly 70% of Kenya’s drug supply, will also experience upward price adjustments as importers factor in higher compliance costs. The Pharmaceutical Society of Kenya estimates that the overall retail cost of life-saving antibiotics and maternal health products will rise by an average of 18.5% across the country within ninety days of the bill's enactment.
The Domestic Manufacturing Disincentive
For more than a decade, the government has incentivized local pharmaceutical manufacturing to build regional resilience. By stripping these manufacturers of their ability to claim input VAT, the Finance Bill 2026 penalizes local value addition in favor of fully finished imports from markets like India and China, which benefit from export subsidies in their home countries. This shift reverses years of progress under the East African Community regional pharmaceutical manufacturing plan, which sought to increase local manufacturing share to 50% by 2027.
A local manufacturer importing raw materials under the new regime will face a direct cash-flow squeeze. Because the finished medicines will be exempt rather than zero-rated, the 16% VAT paid on imported machinery, laboratory reagents, and packaging cannot be recovered. This tax asymmetry places local firms at an immediate 15% cost disadvantage compared to importers of finished drugs. Industry analysts warn that this policy incongruity could stall ongoing capital expenditure plans, including a planned USD 15 million manufacturing plant expansion in Nairobi designed to produce specialized oncology drugs.
This regressive shift also undermines Kenya’s ambitions to become a regional pharmaceutical hub. The East African Community customs protocol allows for the duty-free movement of locally manufactured goods, but if Kenya's internal tax structure inflates the baseline cost of production, Kenyan manufacturers will lose their competitive edge in Uganda, Tanzania, and Rwanda. With the Kenyan shilling currently trading at 130.5 to the US dollar, any additional domestic tax burden will render export pricing uncompetitive compared to direct imports by regional neighbors from Asian producers.
The Fiscal Dilemma and Policy Contradiction
The National Treasury’s push to eliminate zero-rating is driven by a mandate to expand the tax base and reduce the backlog of unpaid VAT refund claims. By converting zero-rated supplies to exempt, the Kenya Revenue Authority (KRA) eliminates the administrative burden of verifying and auditing refund claims from manufacturers. However, this administrative convenience comes at a devastating economic cost, shifting the fiscal burden directly onto sick citizens and weakening the domestic industrial base. The Treasury targets KES 4.2 billion in additional revenue from this shift, but this figure ignores the long-term fiscal strain of subsidizing public hospital acquisitions later.
This strategy directly contradicts the Ministry of Health's rollout of the Social Health Authority (SHA). The transition to SHIF is already facing public skepticism over its 2.75% payroll deduction; adding an artificial 16% cost overhead to the medicines that these public clinics must purchase will quickly deplete the fund’s purchasing power. Consequently, public referral facilities like the Kenyatta National Hospital will face chronic stockouts of essential items, forcing patients back to private pharmacies where they must pay out-of-pocket prices inflated by the new tax policy.
Strategic Outlook for the Pharmaceutical Sector
For now, the fate of Kenya's pharmaceutical supply chain rests in the hands of the National Assembly's Finance and Planning Committee. Unless lawmakers heed the healthcare sector's warnings and reject the proposed VAT shift on medicines, the country risks a dual crisis of diminished healthcare access and a severe contraction of the domestic manufacturing capacity built over the last decade. Corporate players and development partners must present unified financial modeling to the Treasury to demonstrate that the long-term public health costs of this tax shift will far outweigh any short-term revenue gains the government hopes to extract.
